Citations

Clear

44 citation(s) found for "Nguyen, Justin".

Living‐donor Liver Transplantation for Progressive Familial Intrahepatic Cholestasis
Hori, Tomohide , Egawa, Hiroto , Miyagawa‐Hayashino, Aya , Yorifuji, Tohru , Yonekawa, Yukihide, Nguyen, Justin H. , Üemoto, Shinji

Mayo Clinic

World Journal of Surgery | December 1, 2010 | Volume: 35 | Issue: 2 | Pages: 393-402

10.1007/s00268-010-0869-6 | PMID 21125272 Get It

Abstract Background Progressive familial intrahepatic cholestasis (PFIC) results in liver cirrhosis during the disease course, although the etiology includes unknown mechanisms. Some PFIC patients require liver transplantation (LT). Methods In this study, 11 patients with PFIC type 1 (PFIC1) and 3 patients with PFIC type 2 (PFIC2) who underwent living‐donor LT (LDLT) were evaluated. Results Digestive symptoms after LDLT were confirmed in 10 PFIC1 recipients (90.9%); 8 PFIC1 recipients showed steatosis after LDLT (72.7%), which began during the early postoperative period (71.5 ± 55.1 days). Seven of the eight steatosis‐positive PFIC1 recipients (87.5%) showed a steatosis degree of ≥80%, which was complicated with steatohepatitis and resulted in fibrosis. Cirrhotic findings persisted in six PFIC1 recipients even after LDLT (54.5%), and three PFIC1 recipients finally died. The survival rates of the PFIC1 recipients at 5, 10, and 15 years were 90.9%, 72.7%, and 54.5%, respectively. In contrast, the PFIC2 recipients showed good courses and outcomes without any steatosis after LDLT. Conclusions The clinical courses and outcomes after LDLT are still not sufficient in PFIC1 recipients owing to steatosis/steatohepatitis and subsequent fibrosis, in contrast to PFIC2 recipients. PFIC2 is good indication for LDLT. PFIC1 patients require LT during the disease course; therefore, we suggest that the therapeutic strategies for PFIC1 patients, including the timing of LDLT, under the donor limitation should be reconsidered. The establishment of more advanced treatments for PFIC1 patients is required to improve the long‐term prognosis of these patients.
Muromonab‐CD3 therapy for refractory rejections after liver transplantation: a single‐center experience during two decades in Japan
Ueda, Daisuke , Hori, Tomohide , Nguyen, Justin H. , Üemoto, Shinji

Mayo Clinic

Journal of Hepato-Biliary-Pancreatic Sciences | May 10, 2010 | Volume: 17 | Issue: 6 | Pages: 885-891

10.1007/s00534-010-0288-y | PMID 20458505 Get It

AbstractBackground/purposeRefractory rejections still occur in the liver transplantation (LT) field. The aim of this study was to investigate significant factors for the introduction of therapy with muromonab‐CD3 (MCD3) after LT.MethodsA total of 1415 LT patients were retrospectively evaluated, and 11 of the recipients received MCD3 therapy because of steroid‐resistant rejections. The clinical factors before LT and before MCD3 therapy were investigated.ResultsThe recipients were retrospectively divided into two groups based on responses to MCD3 therapy, including their clinical courses after MCD3 therapy and their outcomes. The MCD3 therapy had positive effects in LT recipients with the following four factors: low score of model for end‐stage liver disease or pediatric end‐stage liver disease; earlier time point of the first incidence of rejection; more frequent steroid pulse therapy (SPT) within 2 weeks after LT; and the expression of CD3 in the peripheral blood before MCD3 introduction.ConclusionOptimal induction of MCD3 triggered recovery from refractory rejections, especially in LT recipients in a stable condition, but not in those in a critical or compromised condition.
Authors' reply: interposition graft with polytetrafluoroethylene for mesenteric and portal vein reconstruction after pancreaticoduodenectomy (Br J Surg 2009; 96: 247–252)
Nguyen, Justin H.

Mayo Clinic

British Journal of Surgery | May 11, 2009 | Volume: 96 | Issue: 6 | Pages: 692-693

10.1002/bjs.6672 Get It

Interposition graft with polytetrafluoroethylene for mesenteric and portal vein reconstruction after pancreaticoduodenectomy
Stauffer, John , Dougherty, Marjorie K., Kim, G.P., Nguyen, Justin H. , A Stauffer, John

Mayo Clinic

British Journal of Surgery | February 17, 2009 | Volume: 96 | Issue: 3 | Pages: 247-252

10.1002/bjs.6483 | PMID 19224515 Get It

Abstract Background Portal vein–superior mesenteric vein resection is frequently required after surgical resection of tumours of the pancreas head. The ideal graft for portal vein reconstruction (PVR) remains undefined. Methods Between May 2000 and July 2007, 28 patients had portal vein–superior mesenteric vein resection and PVR during pancreaticoduodenectomy. Their clinical reports were reviewed retrospectively with specific attention to the methods of PVR and outcomes. Results Ten patients had PVR with primary anastomosis, seven had PVR with autologous vein, one had a polytetrafluoroethylene (PTFE) patch, one did not have PVR and nine had PVR with a PTFE interposition graft. There was no infection after PTFE grafting. Six patients had PVR thrombosis after surgery: four after primary anastomosis, one after interposition PTFE and one after vein repair. Conclusion PTFE appeared to be an effective and safe option as an interposition graft for portomesenteric venous reconstruction after pancreaticoduodenectomy.